MAB393

antibody from R&D Systems

Targeting: PPBP b-TG1, Beta-TG, CTAP3, CTAPIII, CXCL7, LA-PF4, LDGF, MDGF, NAP-2, NAP-2-L1, PBP, SCYB7, TGB, TGB1, THBGB1

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Blocking/Neutralizing (Supportive data in Antibodypedia)

Antibody Data

Product number

MAB393

Provider

R&D Systems

Product name

Human CXCL7/NAP-2 Antibody

Antibody type

Monoclonal

Description

Protein A or G purified from hybridoma culture supernatant. Detects human CXCL7/NAP-2 in ELISAs and Western blots. In sandwich ELISAs, less than 0.05% cross-reactivity with recombinant human (rh) CXCL1, 2, 3, 5, 6, 8, 9, 10, or 12 is observed. In Western blots, no cross-reactivity with rhCXCL1, 2, 3, 5, 6, 8, 9, 10, 12, 13, recombinant mouse CXCL1, 2, 6, 9, 10, 12 or recombinant rat CXCL1, 2 or 3 is observed.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antigen sequence

P02775


Isotype

IgG

Antibody clone number

59418

Vial size

500 ug

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

Development of a Glycosaminoglycan Derived, Selectin Targeting Anti-Adhesive Coating to Treat Endothelial Cell Dysfunction.

Wodicka JR, Chambers AM, Sangha GS, Goergen CJ, Panitch A
Pharmaceuticals (Basel, Switzerland) 2017 Mar 29;10(2)

---

Effect of platelet-derived β-thromboglobulins on coagulation.

Egan K, van Geffen JP, Ma H, Kevane B, Lennon A, Allen S, Neary E, Parsons M, Maguire P, Wynne K, O' Kennedy R, Heemskerk JWM, Áinle FN
Thrombosis research 2017 Jun;154:7-15

---

Up-regulation of platelet activation in hemophilia A.

van Bladel ER, Roest M, de Groot PG, Schutgens RE
Haematologica 2011 Jun;96(6):888-95

---

High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study.

Snoep JD, Roest M, Barendrecht AD, De Groot PG, Rosendaal FR, Van Der Bom JG
Journal of thrombosis and haemostasis : JTH 2010 May;8(5):906-13

---

Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.

Smith C, Damås JK, Otterdal K, Øie E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Frøland SS, Hansson GK, Aukrust P
Journal of the American College of Cardiology 2006 Oct 17;48(8):1591-9

Western blot

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Detection of Human CXCL7/NAP-2 by Simple Western^TM. Simple Western lane view shows lysates of human platelets, loaded at 0.2 mg/mL. A specific band was detected for CXCL7/NAP-2 at approximately 10 kDa (as indicated) using 10 µg/mL of Mouse Anti-Human CXCL7/NAP-2 Monoclonal Antibody (Catalog # MAB393) . This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Blocking/Neutralizing

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Myeloperoxidase Release Induced by CXCL7/NAP-2 and Neutralization by Human CXCL7/NAP-2 Antibody. Recombinant Human CXCL7/NAP-2 (Catalog # 393-NP) induces myeloperox-idase release in the cytochalasin-B treated human neutrophils in a dose-dependent manner (orange line). Myeloperoxidase Release elicited by Recombinant Human CXCL7/NAP-2 (1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CXCL7/ NAP-2 Monoclonal Antibody (Catalog # MAB393). The ND₅₀ is typically 15-20 µg/mL in the presence of cytochalasin-B.